switching from compounded tirzepatide to mounjaro vs. What to know about switching

We take this episode to another realm

Conclusions: In real-world practice, injectable semaglutide was associated with descriptive changes in metabolic parameters in patients with ESRD, including those on hemodialysis

Its crucial to understand that while some weight reduction may occur as a side effect, Mounjaro is not approved for weight loss treatment

Additionally, longitudinal studies are crucial for evaluating the efficacy and safety of these treatments, particularly in vulnerable populations, such as adolescents and individuals with pre-existing conditions

Studies have also shown that people who stop taking GLP-1s may regain the weight theyve lost

Because of this gap, clinical advice often leans on what we know about how these medications behave in the body and whats considered possible in theory, rather than large studies in breastfeeding families